The incidence of brain metastases in breast cancer according to molecular subtype and stage: a 10-year single institution analysis

Abstract

BackgroundBreast cancer (BC) is the second most common etiology of brain metastases (BrM). We aimed to examine the incidence of BrM among all BC patients presenting to a large tertiary cancer centre over one decade. MethodsWe included all BC patients presenting consecutively between 2009 and 2019 and cross referenced that cohort to a radiotherapy database, identifying patients treated for BrM at any time following their initial presentation. Cumulative incidences (CI) of BrM diagnoses were calculated using death as a competing risk and compared using the Fine-Gray method. Overall survival was estimated using the Kaplan Meier method. ResultsWe identi ed 12,995 unique patients. The CI of BrM in patients who initially presented with Stage 0-4 disease was 2.1%, 3.7%, 9.4%, 10.6%, and 28.7%, respectively at 10 years. For 8,951 patients with available molecular subtype data, 6,470 (72%), 961 (11%), 1,023 (11%), and 497 (6%) had hormonereceptor (HR)-positive/ERBB2-, HR-negative/ERBB2-, HR-positive/ERBB2+, and HR-negative/ERBB2+ disease, respectively; the CI of BrM in each was 7.6%, 25.3%, 24.1%, and 26.6%, at 10 years following BC diagnosis, respectively. Median overall survival (OS) following BC diagnosis and BrM diagnosis was 28 years 95% CI [25, 32] and 10 months 95% CI [9,12], respectively. ConclusionsFrom a large, registry-based study, we observed that patients with ERBB2+ and triple negative BC have the highest incidence of BrM. Clinicians should have a low threshold for brain imaging in patients with a history of BC who experience symptoms suggestive of BrM, especially in ERBB2+ and triple negative BC.